125 related articles for article (PubMed ID: 6469517)
21. Preclinical studies of the combination of mafosfamide (Asta-Z 7654) and etoposide (VP-16-213) for purging leukemic autologous marrow.
Tamayo E; Hervé P
Exp Hematol; 1988 Feb; 16(2):97-101. PubMed ID: 3276544
[TBL] [Abstract][Full Text] [Related]
22. Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide.
Plowchalk DR; Mattison DR
Toxicol Appl Pharmacol; 1991 Mar; 107(3):472-81. PubMed ID: 2000634
[TBL] [Abstract][Full Text] [Related]
23. Influence of diuretics on urinary general base catalytic activity and cyclophosphamide-induced bladder toxicity.
Sladek NE; Smith PC; Bratt PM; Low JE; Powers JF; Borch RF; Coveney JR
Cancer Treat Rep; 1982 Nov; 66(11):1889-1900. PubMed ID: 7139634
[TBL] [Abstract][Full Text] [Related]
24. Chemical characterization of ASTA Z 7557 (INN mafosfamide, CIS-4-sulfoethylthio-cyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide.
Niemeyer U; Engel J; Scheffler G; Molge K; Sauerbier D; Weigert W
Invest New Drugs; 1984; 2(2):133-9. PubMed ID: 6469506
[TBL] [Abstract][Full Text] [Related]
25. Antineoplastic activity of ASTA Z 7557 (INN mafosfamide) in transplanted and autochthonous experimental rodent tumors.
Zeller WJ; Berger MR; Matys R; Schuhmacher J
Invest New Drugs; 1984; 2(2):175-80. PubMed ID: 6469512
[TBL] [Abstract][Full Text] [Related]
26. Cytotoxicity and DNA cross-linking activity of 4-sulfidocyclophosphamides in mouse leukemia cells in vitro.
Erickson LC; Ramonas LM; Zaharko DS; Kohn KW
Cancer Res; 1980 Nov; 40(11):4216-20. PubMed ID: 7471062
[TBL] [Abstract][Full Text] [Related]
27. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
28. Cross-linking of DNA in L1210 cells and nuclei treated with cyclophosphamide and phosphoramide mustard.
Surya YA; Rosenfeld JM; Hillcoat BL
Cancer Treat Rep; 1978 Jan; 62(1):23-9. PubMed ID: 564237
[TBL] [Abstract][Full Text] [Related]
29. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.
Skórski T; Kawalec M
Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151
[TBL] [Abstract][Full Text] [Related]
30. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
[TBL] [Abstract][Full Text] [Related]
31. Mafosfamide (ASTA-Z-7654) in vitro treatment of bone marrow does not eradicate Philadelphia-positive cells in chronic myeloid leukaemia.
Mortensen BT; Ernst P; Philip P
Eur J Haematol; 1988 Sep; 41(3):218-22. PubMed ID: 3181395
[TBL] [Abstract][Full Text] [Related]
32. Effect of microsomal enzyme modifiers on toxicity and therapeutic activity of cyclophosphamide in mice.
Hart LG; Adamson RH
Arch Int Pharmacodyn Ther; 1969 Aug; 180(2):391-401. PubMed ID: 5348409
[No Abstract] [Full Text] [Related]
33. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
Lelieveld P; van Putten LM
Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
[TBL] [Abstract][Full Text] [Related]
34. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
Klubes P; Cerna I
Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
[TBL] [Abstract][Full Text] [Related]
35. Effect of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or cyclophosphamide on spleen colony-forming units and survival time of leukemic mice.
Vadlamudi S; Waravdekar VS; Choudry JN; Goldin A
Cancer Res; 1968 Jul; 28(7):1242-9. PubMed ID: 5665982
[No Abstract] [Full Text] [Related]
36. Immune manipulation by BCG administered before or after cyclophosphamide for chemo-immunotherapy of L1210 leukaemia.
Mathé G; Halle-Pannenko O; Bourut C
Eur J Cancer (1965); 1974 Oct; 10(10):661-6. PubMed ID: 4465103
[No Abstract] [Full Text] [Related]
37. Successful purging of murine plasmacytoma by mafosfamide (ASTA-Z).
Weiss L; Slavin G; Reich S; Sidi H; Slavin S
Bone Marrow Transplant; 1994 Jan; 13(1):27-30. PubMed ID: 8019450
[TBL] [Abstract][Full Text] [Related]
38. Prevention of cyclophosphamide-induced urotoxicity by reduced glutathione and its effect on acute toxicity and antitumor activity of the alkylating agent.
Tofanetti O; Cavalletti E; Besati A; Pratesi G; Pezzoni G; Zunino F
Cancer Chemother Pharmacol; 1985; 14(3):188-93. PubMed ID: 3995681
[TBL] [Abstract][Full Text] [Related]
39. L-cysteine prodrug protects against cyclophosphamide urotoxicity without compromising therapeutic activity.
Roberts JC; Francetic DJ; Zera RT
Cancer Chemother Pharmacol; 1991; 28(3):166-70. PubMed ID: 1855273
[TBL] [Abstract][Full Text] [Related]
40. ASTA-Z 7557 impairs human natural killer (NK) cell activity.
Condiotti R; Slavin S; Nagler A
Leuk Res; 1996 Feb; 20(2):169-74. PubMed ID: 8628016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
